Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Chembio Diagnostics stock

Learn how to easily invest in Chembio Diagnostics stock.

Chembio Diagnostics is a diagnostics & research business based in the US. Chembio Diagnostics shares (CEMI) are listed on the NASDAQ and all prices are listed in US Dollars. Chembio Diagnostics employs 337 staff and has a trailing 12-month revenue of around $59.8 million.

How to buy Chembio Diagnostics stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – CEMI. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award


  • Trade stocks and ETFs for $0 and no annual fee
  • Minimum deposit of $10 required
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Chembio Diagnostics stock price (NASDAQ: CEMI)

Use our graph to track the performance of CEMI stocks over time.

Chembio Diagnostics shares at a glance

Information last updated 2023-02-01.
Latest market close$0.44
52-week range$0.19 - $1.24
50-day moving average $0.29
200-day moving average $0.52
Wall St. target price$8.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.43

Buy Chembio Diagnostics stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Chembio Diagnostics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Chembio Diagnostics price performance over time

Historical closes compared with the close of $0.44 from 2023-02-01

1 week (2023-01-27) 25.71%
1 month (2022-12-30) N/A
3 months (2022-10-30) N/A
6 months (2022-07-30) N/A
1 year (2022-02-03) -53.19%
2 years (2021-02-03) -94.02%
3 years (2020-02-03) 4.09
5 years (2018-02-02) 8.2

Chembio Diagnostics financials

Revenue TTM $59.8 million
Gross profit TTM $12.8 million
Return on assets TTM -22%
Return on equity TTM -110.81%
Profit margin -60.93%
Book value $0.50
Market capitalisation $13.2 million

TTM: trailing 12 months

Chembio Diagnostics share dividends

We're not expecting Chembio Diagnostics to pay a dividend over the next 12 months.

Have Chembio Diagnostics's shares ever split?

Chembio Diagnostics's shares were split on a 1:8 basis on 29 May 2012. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Chembio Diagnostics shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Chembio Diagnostics shares which in turn could have impacted Chembio Diagnostics's share price.

Chembio Diagnostics share price volatility

Over the last 12 months, Chembio Diagnostics's shares have ranged in value from as little as $0.19 up to $1.24. A popular way to gauge a stock's volatility is its "beta".

CEMI.US volatility(beta: 1.72)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Chembio Diagnostics's is 1.7196. This would suggest that Chembio Diagnostics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Chembio Diagnostics overview

Chembio Diagnostics, Inc. , together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.

Frequently asked questions

What percentage of Chembio Diagnostics is owned by insiders or institutions?
Currently 1.077% of Chembio Diagnostics shares are held by insiders and 8.601% by institutions.
How many people work for Chembio Diagnostics?
Latest data suggests 337 work at Chembio Diagnostics.
When does the fiscal year end for Chembio Diagnostics?
Chembio Diagnostics's fiscal year ends in December.
Where is Chembio Diagnostics based?
Chembio Diagnostics's address is: 555 Wireless Boulevard, Hauppauge, NY, United States, 11788
What is Chembio Diagnostics's ISIN number?
Chembio Diagnostics's international securities identification number is: US1635722093
What is Chembio Diagnostics's CUSIP number?
Chembio Diagnostics's Committee on Uniform Securities Identification Procedures number is: 163572209

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site